【摘要】 目的:观察长春瑞滨(NVB)联合铂类方案对蒽环类和紫杉类药物耐药的转移性乳腺癌患者的疗效及安全性。方法:选取2010年1月至2013年12月广西医科大学附属肿瘤医院收治的55例经蒽环类药物和紫杉类药物治疗失败后的转移性乳腺癌患者,采用NVB联合顺铂(DDP)(NP方案)或NVB联合卡铂(CBP)(NC方案)治疗:NVB 25 mg/m~2,静脉滴注,第1、第5天;DDP 25 mg/m~2,静脉滴注,第1~3天;或CBP浓度-时间曲线下面积(AUC)=5,静脉滴注,第1天。每21 d为1个治疗周期。结果:55例患者中,完全缓解(CR)2例(3.6%),部分缓解(PR)20例(36.4%),稳定(SD)18例(32.7%),进展(PD)15例(27.3%),总缓解率(ORR)为40.0%(22/55),疾病控制率(DCR)为72.7%(40/55)。中位无病生存期(PFS)为6个月(95%CI:3.1~8.9)。最常见的不良反应是呕吐和骨髓抑制,其中达到Ⅲ级及以上的不良反应发生率:呕吐9.1%,中性粒细胞减少21.8%,血小板减少5.5%。所有不良反应均为可逆性,无治疗相关性死亡。结论:NVB联合铂类方案在蒽环类药物和紫杉类药物一线方案治疗失败后的转移性乳腺癌患者中具有较好的疗效,且患者耐受性好,是可选的方案。更多还原

【Abstract】 Objective: To investigate the efficacy and safety of navelbine(NVB)plus platinum protocol in metastatic breast cancer(MBC)patients with drug-resistant to anthracyclines and taxanes. Methods: MBC patients previously treated with anthracyclines and taxanes were enrolled. Treatment consisted of NVB(25 mg/m~2 i. v.on days 1 and 5)and cisplatin(25 mg/m~2 i. v. on days 1 to 5)or carboplatin(AUC 5 i. v. on day 1)administered every 21 days. Results: Objective response rate was 40. 0% including 2 complete response(3. 6%)and 20 partial responses(36. 4%). Eighteen patients(32. 7%)had stable disease. The median progression-free survival(PFS)was 6 months(95% CI 3. 1-8. 9 months). The most common grade 3-4 toxicities included vomiting(9. 1%),neutropenia(21. 8%),and thrombocytopenia(5. 5%). All adverse events were reversible and no treatment-related death. Conclusion: NVB plus cisplatin or carboplatin had promising efficacy in MBC patients with drug-resistant to anthracyclines and taxanes. This combination could improve patients’ tolerability.更多还原